BioPharmSignal logoBioPharmSignal

Biotech News

CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026

CRISPR Therapeutics (CRSP)CRISPR TherapeuticsConference / presentation

-Data presented in a late-breaking presentation at the European Society of Cardiology (ESC) Congress 2026- -Phase 1a clinical data for CTX310 ® continued to demonstrate robust, dose-dependent reductions in circulating ANGPTL3 with a mean reduction from baseline of 79% (maximum 89%), a mean

Related news

CRSPCRISPR Therapeutics2026-09-08 12:30 EST

CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

CRSPCRISPR Therapeutics2026-05-28 12:00 EST

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

SANASana Biotechnology2026-05-12 20:05 EST

Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs

NTLAIntellia2026-09-04 12:00 EST

Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference

SRPTSarepta Therapeutics2026-08-31 20:30 EST

Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

SRPTSarepta Therapeutics2026-05-13 20:30 EST

Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

SANASana Biotechnology2026-07-01 13:00 EST

Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026

CRBUCaribou2026-06-29 12:00 EST

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

CRBUCaribou2026-05-27 20:05 EST

Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference

VYGRVoyager Therapeutics2026-04-27 20:31 EST

Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease

View all latest news

CRISPR Therapeutics

Gene-Based Medicine Platform CRISPR Therapeutics develops gene-edited medicines across hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare disease. Its toolkit includes CRISPR/Cas9, the SyNTase editing platform, lipid-nanoparticle delivery and engineered cell therapies. CASGEVY CASGEVY...

Recent company news

CRSPCRISPR Therapeutics2026-09-08 12:30 EST

CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

CRSPCRISPR Therapeutics2026-08-28 14:31 EST

CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026

CRSPCRISPR Therapeutics2026-08-03 20:15 EST

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

CRSPCRISPR Therapeutics2026-05-28 12:00 EST

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

CRSPCRISPR Therapeutics2026-05-06 12:30 EST

CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference

Stock data

Close
57.33 USD
Market cap
5.02B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States